Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

J Joshua Rivera (1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) Q Qi Yan (State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University) S Saeed Daneshmandi R Romain Lannes E Eriko Katsuta J JeeEun Choi (3Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY) P Prashant Singh (Ames National Laboratory) A Ahmed Belal (6Department of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY) R Ronald Alberico (6Department of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY) I Ian Lund (7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY) M Megan Schaefer (7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY) H Hamza Hassan (7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY) S Sarah Parker K Kenneth C. Anderson N Nikhil C. Munshi M Mehmet Samur (2Department of Data Science, Dana-Farber Cancer Institute, Boston) P Philip L. McCarthy J Jens Hillengass (Roswell Park Comprehensive Cancer Center) H Hemn Mohammadpour

Abstract

Abstract Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting multiple myeloma (MM). Neutrophils are a new cancer research focus due to their potential to reduce the efficacy of immune-based therapies. This study aimed to deepen understanding of neutrophil function in MM by analyzing freshly isolated myeloid cells from paired focal lesions (FLs) and bone marrow using single-cell RNA sequencing, immunofluorescence imaging, and functional assays. We describe 3 distinct CXCR2+ mature neutrophil subsets: TREM1+CD10+, RETN+LCN2+, and TNFAIP3+CXCL8+, each exhibiting unique phenotypes within the TME. Notably, the TREM1+CD10+ subset was highly prevalent, particularly in FLs, demonstrating potent immunosuppressive effects on T cells. This subset’s gene signature was correlated with shorter overall survival (OS) in a large data set of patients with MM, underscoring its clinical significance. Targeted inhibition of neutrophil activity through CXCR2 blockade, alone or combined with standard anti-MM therapies, significantly reduced tumor burden, improving OS in preclinical MM models. These insights into neutrophil-mediated immunosuppression in MM provide valuable knowledge regarding mechanisms driving immune evasion, and reveal new therapeutic approaches to enhance the efficacy of MM treatment.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 20
Published November 13, 2025
Pages 2392-2405
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (19)

J

Joshua Rivera

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Q

Qi Yan

State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University

S

Saeed Daneshmandi

R

Romain Lannes

E

Eriko Katsuta

J

JeeEun Choi

3Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

P

Prashant Singh

Ames National Laboratory

A

Ahmed Belal

6Department of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

R

Ronald Alberico

6Department of Diagnostic Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, NY

I

Ian Lund

7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

M

Megan Schaefer

7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

H

Hamza Hassan

7Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

S

Sarah Parker

K

Kenneth C. Anderson

N

Nikhil C. Munshi

M

Mehmet Samur

2Department of Data Science, Dana-Farber Cancer Institute, Boston

P

Philip L. McCarthy

J

Jens Hillengass

Roswell Park Comprehensive Cancer Center

H

Hemn Mohammadpour